Paulo Lucio

Lisbon, 1400038, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.

Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.

Journal: Journal of clinical medicine
Published: September 01, 2025

Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group

Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group

Journal: Acta medica portuguesa
Published: January 20, 2025

The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.

The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.

Journal: EJHaem
Published: July 25, 2024

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Journal: The Lancet. Oncology
Published: May 06, 2024

Differential activation of basal and IL-7-induced PI3K/Akt/ mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia.

Differential activation of basal and IL-7-induced PI3K/Akt/ mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia.

Journal: Haematologica
Published: August 18, 2023

Evaluation of Semiautomatic and Deep Learning-Based Fully Automatic Segmentation Methods on [18F]FDG PET/CT Images from Patients with Lymphoma: Influence on Tumor Characterization.

Evaluation of Semiautomatic and Deep Learning-Based Fully Automatic Segmentation Methods on [18F]FDG PET/CT Images from Patients with Lymphoma: Influence on Tumor Characterization.

Journal: Journal of digital imaging
Published: January 03, 2023

Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma

Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma

Journal: Acta medica portuguesa
Published: September 02, 2022

Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study.

Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study.

Journal: Frontiers in oncology
Published: January 23, 2022

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness.

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness.

Journal: PharmacoEconomics
Published: December 24, 2020

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Journal: BMC cancer
Published: September 29, 2020

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Journal: Leukemia & lymphoma
Published: April 10, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026